Duarte, CANCT07613385Now EnrollingIRB Ready

Relapsed/Refractory Acute Myeloid Leukemia (AML) Clinical Trial in Duarte, CA

Access cutting-edge relapsed/refractory acute myeloid leukemia (aml) treatment through this clinical trial at a research site in Duarte. Study-provided care at no cost to qualified participants.

Sponsored by City of Hope Medical Center

Quick Self-Assessment

See if you qualify for this Duarte location

Preparing your pre-screening questions…

Expert Care in Duarte

Access relapsed/refractory acute myeloid leukemia (aml) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related relapsed/refractory acute myeloid leukemia (aml) treatment provided free

Apply for This Duarte Location

Check if you qualify for this relapsed/refractory acute myeloid leukemia (aml) clinical trial in Duarte, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Duarte

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Duarte site if eligible
  4. 4Begin participation

About This Relapsed/Refractory Acute Myeloid Leukemia (AML) Study in Duarte

Every patient responds differently to their cancer treatment, and some treatments work better for some patients more than others. For patients with relapsed, refractory ( R/R) AML, there may be fewer approved treatment options remaining. In this research study, the investigators are testing whether high throughput drug screening (HTS) in combination with robust molecular testing by HopeSeq (includes DNA sequencing for \>500 genes and 160 gene rearrangements and RNAseq for \>5,000 genes) can help doctors determine which treatment might work best for each individual patient. HTS tests how the patient's own AML cells respond to different treatment options including individual drugs and triple drug regimens and recommends for the best treatment options for an individual patient. Participants will provide extra bone marrow and/or blood at the time of routine procedure, and these extra sample(s) will be tested using the Cancer Drug Sensitivity Test ( CDST) HTS, CLIA approved in Washington state since 2014. A committee (the Functional Molecular Tumor Board) will review the HopeSeq and HTS results, past treatments, and clinical description, and give a recommendation for the best AML treatment options for each individual patient. The patient's doctor will get a copy of the recommendation and discuss treatment options with the patient. The patient and their doctor will decide on the best treatment plan for the patient, one which will be approved by insurance. Patients will not be treated with any drugs as part of this study. Then at 6 and 12 months, there will be retrospective review of medical records to determine how will the testing predicted the response, drug sensitivity or resistance, and overall and disease-free survival will be monitored.

Sponsor: City of Hope Medical Center

Who Can Participate

Inclusion Criteria

Documented informed consent of the participant and/or legally authorized representative.
Agreement to allow the use of archival tissue from diagnostic tumor biopsies
Age: ≥ 18 years
ECOG ≤ 3 (Appendix A)
Patients with histologically confirmed AML according to ICC or WHO criteria, and
Refractory/relapsed (R/R) to prior treatment with one or more regimens if adverse risk or two or more regimens if favorable/intermediate risk (Appendix B)
Sufficient bone marrow and/or peripheral blood sample (archival or fresh) to run the high throughput screening (HTS; Estimate sufficient if circulating blast count of 5,000 or greater or cellular marrow with greater than or equal to 20% blasts.) Otherwise,
Sufficient cells flushed from bone marrow biopsy, if bone marrow is not aspirable, OR
Extramedullary disease, if it is possible to obtain a fluid or biopsy sample from that location
Expected survival is greater than 100 days.
Fully recovered from the acute toxic effects (except alopecia) to ≤ Grade 1 to prior anti-cancer therapy

Exclusion Criteria

Treatment with any chemotherapeutic agent necessary to control AML burden is permitted between day -18 and -1.
Must not have received or planning to receive live vaccine while being on study
Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (FAB class M3-AML)
Active central nervous system (CNS) disease (OK if treated and responding)
Active graft vs host disease (GVHD)
Unstable cardiac disease as defined by one of the following:
Cardiac events such as myocardial infarction (MI) within the past 6 months
Uncontrolled atrial fibrillation or hypertension
Clinically significant uncontrolled illness
Uncontrolled active infection
Females only: Pregnant or breastfeeding
Any other condition or active malignancy that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Duarte?

Yes, this clinical trial (NCT07613385) has an active research site in Duarte, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Relapsed/Refractory Acute Myeloid Leukemia (AML) Treatment Options in Duarte, CA

If you're searching for relapsed/refractory acute myeloid leukemia (aml) treatment options in Duarte, CA, this clinical trial (NCT07613385) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Duarte research site is actively enrolling participants for this clinical trial. You'll receive care from experienced relapsed/refractory acute myeloid leukemia (aml) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all relapsed/refractory acute myeloid leukemia (aml) clinical trials near you to find additional studies recruiting in your area.

Ready to Join in Duarte?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Duarte, CA